Fuori onda

Storia in evoluzione · 1 servizio

Moderna-Merck melanoma vaccine trial

Prima messa in onda Ultima messa in onda

In corsoProssima verifica il : Further trial follow-up, safety findings and company announcements, including final results.

A che punto è

On August 19, Moderna and Merck reported unpublished topline results showing their personalized vaccine plus Keytruda reduced the risk of recurrence or spread of high-risk advanced melanoma compared with Keytruda alone. The trial’s final results and follow-up have not yet been reported.

CronistoriaGiorno 1

1 servizio11 testate11 fonti1 video

  • Ancora nessun evento datato
    1. Aggiornamento 1A One-Person Shot Delayed Melanoma's Return. The Proof Is Still Missing.

    La storia finora

    1. Aggiornamento 1

      A One-Person Shot Delayed Melanoma's Return. The Proof Is Still Missing.

      Merck and Moderna say their personalized mRNA plus Keytruda met two recurrence endpoints in high-risk melanoma — but with no numbers, no safety data and no paper, scale and approval remain unproven.

      Ancora aperto dopo questo servizio

      • No magnitude of benefit, hazard ratios, absolute risk reduction, overall survival, durability, safety details, cost, turnaround time, or FDA review timeline is established on this record.
      • The exact enrollment number and the size and durability of the market move at a single agreed timepoint are not established.

    Cronologia

    1. Aperta1 servizio

    Chi è coinvolto

    Luoghi

    • United StatesUnited States1 servizio

    Tutte le testate che abbiamo letto su questa storia

    11 fonti11 testate1 video